A study of HS-10516 for VHL syndrome tumors
Part of Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation clinical trials.
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old
- You have either advanced clear cell kidney cancer or a tumor related to VHL syndrome
- You are able to take care of yourself (ECOG 0 or 1) and expected to live at least 3 months
- You agree to use birth control during the study and are not pregnant or nursing
- You cannot have had certain cancer treatments or major surgery within the last few weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
This trial tests a new drug called HS-10541, which may target a specific genetic change in your tumor (KRAS G12C mutation). The study aims to see if this drug is safe and effective, either alone or with other cancer treatments, for people with advanced cancer that hasn't responded to standard therapy.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This trial tests a special imaging agent that targets a protein found in tumors related to Von Hippel-Lindau (VHL) disease. It may help doctors better detect and monitor these tumors.
Hear when a new Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.